EU Rare Disease Policy Needs To Help Revive Abandoned Candidates & Repurpose Existing Drugs

 
• By Eliza Slawther
  
Abandoned house
Sponsors could revisit abandoned orphan drug candidates • Source: Shutterstock

More from Health Technology Assessment

More from Market Access